Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
- 23 November 2018
- journal article
- review article
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 127 (02/03) , 109-116
Abstract
Adrenocortical carcinoma is a rare endocrine malignant disease with a generally unfavorable but heterogeneous prognosis. Although even in advanced stages a subset of patients experiences long-term disease stabilisation, effective systemic treatment options are limited. Mitotane is the only approved drug and the combination of etoposide, doxorubicin and cisplatin (plus mitotane) is currently considered as treatment standard for advanced adrenocortical carcinoma based on the results of a large randomized phase III trial. However, progression-free survival is often limited and further treatment options are frequently needed. Here we summarize the current knowledge about second and third-line therapeutic modalities (local and systemic) in advanced disease. Following the recent ESE-ENSAT guidelines local therapies play an important role for these patients. Regarding systemic therapies the best data are available for gemcitabine+capecitabine or streptozotocin (both with or without mitotane). Furthermore, we introduce our own approach to patients with advanced adrenocortical carcinoma based on our experience as a large multidisciplinary clinic dedicated to the care of patients with this orphan disease.Keywords
This publication has 65 references indexed in Scilit:
- Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinomaEuropean Journal of Endocrinology, 2012
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideBlood, 2011
- Transcatheter Arterial Chemoembolization for Liver Metastases in Patients with Adrenocortical CarcinomaJournal of Vascular and Interventional Radiology, 2010
- Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaCancer Chemotherapy and Pharmacology, 2009
- Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2009
- Adjuvant Mitotane Treatment for Adrenocortical CarcinomaNew England Journal of Medicine, 2007
- Prognostic Parameters of Metastatic Adrenocortical CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2007
- Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane TherapyNew England Journal of Medicine, 1990
- Treatment of hormone-producing adrenocortical cancer with o,p'DDD and streptozocinCancer, 1987
- Adrenal cortical carcinoma. A clinical and pathologic study of 49 casesCancer, 1979